Navamedic ASA Celebrates First Approval of Innovative Medical Device OraFID® for Pharmaceuticals Navamedic ASA has received the green light for its medical device, OraFID®, marking a significant advancement in pharmaceutical delivery systems for personalized treatments.

Navamedic ASA Celebrates First Approval of Innovative Medical Device OraFID® for Pharmaceuticals #Norway #Oslo #Navamedic #OraFID #Flexilev

Navamedic ASA Broadens its Horizons with Acquisition in Addiction Treatment Sector Navamedic ASA has announced its acquisition of dne pharma to enter the addiction treatment market and plans a rights issue to finance the deal.

Navamedic ASA Broadens its Horizons with Acquisition in Addiction Treatment Sector #Norway #Oslo #Addiction_Treatment #Navamedic #dne_pharma

Navamedic Sees Impressive Growth in Q1 2025, Sets Expansive Future Focus Navamedic ASA reports a robust start to 2025 with a 9.2% revenue increase, fueled by strategic initiatives and solid performance in key segments.

Navamedic Sees Impressive Growth in Q1 2025, Sets Expansive Future Focus #pharmaceuticals #Norway #Oslo #Q1_2025 #Navamedic

Lämnar #Navamedic +15% för att köpa storebrodern #Novo som handlas till p/e 15-16 på årets vinster.